Agranulocytosis is the most severe adverse effect of antithyroid drug therapy. The findings of a novel study from Japan suggest that this complication occurs more frequently if higher rather than lower starting doses of the thionamide drug methimazole are prescribed. Has the time come to reassess current therapy regimens?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cooper, D. S. Antithyroid drugs. N. Engl. J. Med. 352, 905–917 (2005).
Tajiri, J. & Noguchi, S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 14, 459–462 (2004).
Takata, K. et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19, 559–563 (2009).
Pearce, S. H. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin. Endocrinol. (Oxf.) 61, 589–594 (2004).
Nakamura, H. et al. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J. Clin. Endocrinol.Metab. 92, 2157–2162 (2007).
Abraham, P., Avenell, A., Park, C. M., Watson, W. A. & Bevan, J. S. A systematic review of drug therapy for Graves' hyperthyroidism. Eur. J. Endocrinol. 153, 489–498 (2005).
Kim, H. J. et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am. J. Gastroenterol. 96, 165–169 (2001).
Cooper, D. S. & Rivkees, S. A. Putting propylthiouracil in perspective. J. Clin. Endocrinol. Metab. 94, 1881–1882 (2009).
Bahn, R. S. et al. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19, 673–674 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Franklyn, J. Antithyroid therapy—best choice of drug and dose. Nat Rev Endocrinol 5, 592–594 (2009). https://doi.org/10.1038/nrendo.2009.201
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.201
